top of page

Screen Shot 2021-01-12 at 11.44.35 AM.pn

Search

A2A / Daewoong Pharmaceutical Oncology Agreement

A2A Pharma
Feb 7, 2020
1 min read

A2A Pharmaceuticals Inc. Today Announced a Multi-target Co-development Agreement With Daewoong Pharmaceutical for AI-enhanced Oncology Drug Discovery.

LEARN MORE

Recent Posts

FDA Clearance of IND Application for TACC3 PPI Inhibitor A2A-252 in Women's Cancer

FDA Clearance of IND Application for TACC3 PPI Inhibitor A2A-252 in Women's Cancer

A2A co-founded biomea Fusion raises $56M

Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations...

A2A Appoints New Advisors

Dr. Siddhartha Mukherjee, Dr. Annalisa Jenkins and Dr. Srikumar Chellappan join A2A’s Advisory Board. LEARN MORE

Comments

bottom of page